Ann Dermatol.  2018 Apr;30(2):247-249. 10.5021/ad.2018.30.2.247.

Fibrous Plaque of the Eyelid in a Patient with Tuberous Sclerosis Responding to Everolimus

• Park SM
• Kim BS
• Kim MB
• Lee YJ
• Ko HC

• KMID: 2414696
• DOI: http://doi.org/10.5021/ad.2018.30.2.247

Abstract

No abstract available.

MeSH Terms

Everolimus*
Eyelids*
Humans
Tuberous Sclerosis*
Everolimus

Figure

• 

  Fig. 1 (A, B) Erythematous indurated plaque of the left lower eyelid, skin-colored to brownish plaques on the forehead. (C) Decrease in thickness and erythema of the lesion after oral everolimus treatment for 14 months.

• 

  Fig. 2 Histological examination of the eyelid specimen shows fibrovascular proliferation and hyperplasia of hair follicles (H&E; A: ×20, B: ×100).

Reference

1. Jacks SK, Witman PM. Tuberous sclerosis complex: an update for dermatologists. Pediatr Dermatol. 2015; 32:563–570.

2. Torrelo A, Hadj-Rabia S, Colmenero I, Piston R, Sybert VP, Hilari-Carbonell H, et al. Folliculocystic and collagen hamartoma of tuberous sclerosis complex. J Am Acad Dermatol. 2012; 66:617–621.

3. Nathan N, Wang JA, Li S, Cowen EW, Haughey M, Moss J, et al. Improvement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimus. J Am Acad Dermatol. 2015; 73:802–808.

4. Karar J, Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011; 4:51.

5. Zolli C, Rodrigues MM, Shannon GM. Unusual eyelid involvement in tuberous sclerosis. J Pediatr Ophthalmol. 1976; 13:156–158.